Is replacement therapy with nutritional and active forms of vitamin D required in chronic kidney disease mineral and bone disorder?

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 4, 2009, Pages 308-314

  Wesseling Perry, Katherine ^a   Salusky, Isidro B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic kidney disease; mortality; vitamin D

Indexed keywords

22 OXACALCITRIOL; 25 HYDROXYVITAMIN D; CALCITRIOL; CAPTOPRIL; DOXERCALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARICALCITOL; VITAMIN D; VITAMIN D BINDING PROTEIN;

ADYNAMIC BONE DISEASE; BONE; BONE DISEASE; CANCER RISK; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG MEGADOSE; FRACTURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; IMMUNE SYSTEM; INFECTION RISK; MINERAL DEFICIENCY; MORTALITY; NONHUMAN; OSTEOMALACIA; PARATHYROID GLAND; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; REVIEW; RICKETS; SUBSTITUTION THERAPY; TISSUE SPECIFICITY; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

ANIMALS; BONE DISEASES; CALCITRIOL; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; ORGAN SPECIFICITY; PARATHYROID HORMONE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 67849093816     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32832c7654     Document Type: Review

References (90)

1. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945-1953.
2. Martinez I, Saracho R, Montenegro J, Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11 (Suppl 3):22-28.
3. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31-38.
4. Demay MB, Kiernan MS, DeLuca HF, Kronenberg HM. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihy- droxyvitamin D3. Proc Natl Acad Sci USA 1992; 89:8097-8101.
5. Holick MF, Garabedian M. Vitamin D: photobiology, metabolism, mechanism of action, and clinical applications. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th ed. Washington, DC: American Society for Bone and Mineral Research; 2006. pp. 129-137.
6. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80S:1689S-1696S.
7. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006; 116:2062-2072.
8. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93:677-681.
9. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
10. Khaw KT, Sneyd MJ, Compston J. Bone density parathyroid hormone and 25- hydroxyvitamin D concentrations in middle aged women. BMJ 1992; 305:273-277.
11. LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999; 281:1505-1511.
12. K/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S101-S201.
13. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338:777-783.
14. Gordon CM, DePeter KC, Feldman HA, et al. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004; 158:531-537.
15. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205-2215.
16. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate? Bone 2004; 35:1192-1199.
17. Yoshiko Y, Wang H, Minamizaki T, et al. Mineralized tissue cells are a principal source of FGF23. Bone 2007; 40:1565-1573.
18. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770-774.
19. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26:345-348.
20. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64:2272-2279.
21. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117:4003-4008.
22. Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195:125-131.
23. Zehnder D, Landray MJ, Wheeler DC, et al. Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of predialysis patients. The chronic renal impairment in Birmingham (CRIB) study. Nephron Clin Pract 2007; 107:c109-c116.
24. Stavroulopoulos A, Porter CJ, Roe SD, et al. Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. Nephrology (Carlton) 2008; 13:63-67. 25(OH)vitamin D deficiency is associated with increased PTH levels and low bone mineral density in CKD stages 3 and 4.
25. Reichel H, Deibert B, Schmidt-Gayk H, Ritz E. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991; 6:162-169.
26. Saab G, Young DO, Gincherman Y, et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105:c132-c138.
27. Mucsi I, Almasi C, Deak G, et al. Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol 2005; 64:288-294.
28. Coburn JW, Koppel MH, Brickman AS, Massry SG. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 1973; 3:264-272.
29. Holick MF. Vitamin D and the kidney. Kidney Int 1987; 32:912-929.
30. Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982; 1:74-76.
31. Koenig KG, Lindberg JS, Zerwekh JE, et al. Free and total 1,25-dihydroxy- vitamin D levels in subjects with renal disease. Kidney Int 1992; 41:161-165.
32. Saha H. Calcium and vitamin D homeostasis in patients with heavy proteinuria. Clin Nephrol 1994; 41:290-296.
33. Ishimura E, Nishizawa Y, Inaba M, et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999; 55:1019-1027.
34. Mattila C, Knekt P, Mannisto S, et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 2007; 30:2569-2570.
35. Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-Protein binding and post- transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998; 273:5253-5259.
36. Naveh-Many T, Bell O, Silver J, Kilav R. Cis and trans acting factors in the regulation of parathyroid hormone (PTH) mRNA stability by calcium and phosphate. FEBS Lett 2002; 529:60-64.
37. Farrow SM, Hawa NS, Karmali R, et al. Binding of the receptor for 1,25- dihydroxyvitamin D3 to the 5'-flanking region of the bovine parathyroid hormone gene. J Endocrinol 1990; 126:355-359.
38. Hawa NS, O'Riordan JL, Farrow SM. Binding of 1,25-dihydroxyvitamin D3 receptors to the 5′-flanking region of the bovine parathyroid hormone gene. J Endocrinol 1994; 142:53-60.
39. Liu SM, Koszewski N, Lupez M, et al. Characterization of a response element in the 5′-flanking region of the avian (chicken) PTH gene that mediates negative regulation of gene transcription by 1,25- dihydroxyvitamin D3 and binds the vitamin D3 receptor. Mol Endocrinol 1996; 10:206-215.
40. Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92:1436-1443.
41. Szabo A, Merke J, Beier E, et al. 1, 25 (OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35:1049-1056.
42. Canaff L, Hendy GN. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 2002; 277:30337-30350.
43. Gonzalez EA, Martin KJ. Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells. Kidney Int 1996; 50:63-70.
44. Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46:1160-1166.
45. Salusky IB, Kuizon BD, Belin TR, et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 1998; 54:907-914.
46. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279:16754-16766.
47. Kitazawa R, Kitazawa S, Maeda S. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim Biophys Acta 1999; 1445:134-141.
48. Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104:16810-16815.
49. Nakane M, Ma J, Ruan X, et al. Mechanistic analysis of VDR-mediated renin suppression. Nephron Physiol 2007; 107:35-44.
50. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-238.
51. 2vitamin D levels are associated with an increased rate of mortality in cardiac transplant recipients.
52. Kim HW, Park CW, Shin YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 2006; 102:c21-c29.
53. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815-1824.
54. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71:438-441.
55. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihy- droxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 2002; 139:279-284.
56. Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004; 43:877-890.
57. Salusky IB, Goodman WG, Sahney S, et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005; 16:2501-2508.
58. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168:397-403. Therapy with active vitamin D sterols is associated with reduced mortality rates in patients with chronic kidney disease.
59. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16:1115-1125.
60. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72:1004-1013.
61. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70:1858-1865.
62. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349:446-456.
63. Tentori F, Albert JM, Young EW, et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24:963-972. When adjusting for baseline factors, vitamin D sterol therapy was not associated with decreased mortality rates in adult patients treated with maintenance dialysis.
64. Schwarz U, Amann K, Orth SR, et al. Effect of 1, 25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53:1696-1705.
65. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68:2823-2828.
66. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18:2600-2608.
67. Al-Aly Z, Qazi RA, Gonzalez EA, et al. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007; 50:59-68.
68. Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007; 27:36-43.
69. Lambert PW, Stern PH, Avioli RC, et al. Evidence for extrarenal production of 1 alpha, 25-dihydroxyvitamin D in man. J Clin Invest 1982; 69:722-725.
70. Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E. Extra-renal production of calcitriol in chronic renal failure. Kidney Int 1988; 34:368-375.
71. Dusso AS, Finch J, Brown A, et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 1991; 72:157-164.
72. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 2006; 70:654-659.
73. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int 1993; 43:436-442.
74. Salusky IB, Ramirez JA, Oppenheim W, et al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994; 45:253-258.
75. Ghazali A, Fardellone P, Pruna A, et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 1999; 55:2169-2177.
76. Coen G, Mantella D, Manni M, et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 2005; 68:1840-1848.
77. Langman CB, Mazur AT, Baron R, Norman ME. 25-Hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity. J Pediatr 1982; 100:815-820.
78. Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47:263-276.
79. Kim DH, Sabour S, Sagar UN, et al. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008; 102:1540-1544.
80. Pilz S, Marz W, Wellnitz B, et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008; 93:3927-3935. 25(OH)vitamin D deficiency was associated with increased risk of sudden cardiac death in patients with normal kidney function who underwent coronary angiography.
81. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75:88-95. Higher 25(OH)vitamin D levels were associated with improved survival in patients with chronic kidney disease.
82. Avkarogullari M, Bozkurt A, Akpinar O, et al. The relation between serum erythropoietin level and severity of disease and mortality in patients with chronic heart failure. Acta Cardiol 2008; 63:297-302.
83. van der MP, Lok DJ, Januzzi JL, et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 2008; 29:1510-1515.
84. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D- mediated human antimicrobial response. Science 2006; 311:1770-1773.
85. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81:353-373.
86. Gombart AF, Bhan I, Borregaard N, et al. Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis 2009; 48:418-424.
87. Hypponen E, Berry DJ, Wjst M, Power C. Serum 25-hydroxyvitamin D and IgE: a significant but nonlinear relationship. Allergy 2009; 64:613-620.
88. Greer RM, Rogers MA, Bowling FG, et al. Australian children and adolescents with type 1 diabetes have low vitamin D levels. Med J Aust 2007; 187:59-60.
89. Brekke HK, Ludvigsson J. Vitamin D supplementation and diabetes-related autoimmunity in the ABIS study. Pediatr Diabetes 2007; 8:11-14.
90. Schwartz GG, Whitlatch LW, Chen TC, et al. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998; 7:391-395.